SBI Symposium Collection: Challenging Breast Imaging Days Boot Camp

SBI Symposium Collection: Challenging Breast Imaging Days Boot Camp 

False positive and false negative findings contribute to limited sensitivity and specificity of breast imaging exams. Inappropriate characterization and usage of the BI-RADS assessment categories can contribute to inappropriate biopsies or missed breast cancers. Indeed, a recent study found the BI-RADS category 3 malignancy rate to be greater than the accepted limit of 2% for digital mammography. This activity aims to help radiologists gain clinical knowledge necessary to minimize false positive and false negative reads and increase diagnostic accuracy when interpreting mammograms, ultrasound, and MRI. This collection features presentations from the 2023 SBI Symposium.

Challenging Breast Imaging Days Boot Camp Lectures

1) Calcifications: The Good, the Bad, and the Really Ugly

Speakers:

• Elizabeth McDonald, MD, FSBI
• Alison Chetlen, DO, FSBI

2) Distortions and Asymmetries: Detection, Management, and Biopsy

Speakers:

• Liane Philpotts, MD, FSBI
• Kimberly Ray, MD, FSBI
• Shadi Shakeri, MD, FSBI

3) B3 or Not B3: That Is the Question

Speakers:

• Ethan Cohen, MD, FSBI
• Steven Poplack, MD, FSBI
• Roberta Strigel, MD, FSBI

4) Bad Falsies: Minimizing FN and FP

Speakers:

• Lars Grimm, MD, FSBI
• Ana Lourenco, MD, FSBI
• Habib Rahbar, MD, FSBI

Learning Objectives:

• Review differential diagnosis and management of calcifications in axillary lymph nodes
• Identify strategies to minimize false positives and false negatives on mammography, US, and MRI
• Define developing asymmetries and discuss appropriate management
• Describe the appropriate management for architectural distortions
• Discuss clinical scenarios not conducive to BI-RADS 3 assessments / short term imaging follow up
• Describe the mammography, ultrasound, and breast MRI findings that may be appropriately assessed as BI-RADS 3
• Discuss which calcification descriptors are appropriate for the BI-RADS 3 (probably benign) category and which are considered suspicious for malignancy
• Describe the expected frequency of malignancy for BI-RADS 3 lesions

CME Released:  1/16/2024   CME Expires:  1/15/2027

Location: Online

Joint Accreditation Statement - In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Breast Imaging . Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Professions in scope for this activity are listed below. Amedco Joint Accreditation Provider Number: 4008163

Physicians - Amedco LLC designates this material for a maximum of 3.75 AMA PRA Category 1 Credits^TM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learner Notification:

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Breast Imaging . Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Professions in scope for this activity are listed below.

Amedco Joint Accreditation Provider Number: 4008163

Physicians - Amedco LLC designates this material for a maximum of 3.75 AMA PRA Category 1 Credits^TM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name - Commercial Interest: Relationship

Alison Chetlen- NA
Ethan Cohen- NA
Lars Grimm-Hologic:Consultant, Medscape Reference:Scientific/Medical Advisory Board Member
Ana Lourenco- NA
Elizabeth McDonald- NA
Liane Philpotts- NA
Steven Poplack- Johnson & Johnson, Merck Inc:Public Stock Shareholder
Habib Rahbar- Guerbet, LLC:Consultant
Kimberly Ray- NA
Shadi Shakeri- Siemens, BD, Izotropic:Consultant
Roberta Strigel- GE Healthcare:Other
Nuria Gramkee- NA
Ryan Dixon- NA